Approved indications
Gleolan is FDA-approved as an optical imaging agent in adults with suspected high‑grade glioma to help visualize malignant tissue during surgery, serving as an adjunct to standard surgical techniques rather than as a treatment that shrinks the tumor by itself.

Off-label uses
Clinicians may use 5‑aminolevulinic acid–guided surgery in other brain tumors (such as some low‑grade gliomas or other CNS tumors) or in younger patients, but these uses are off-label in the United States and supported mainly by smaller clinical studies and international experience rather than large, definitive U.S. trials.

Efficacy expectations
Gleolan starts working on the day of surgery, with maximal tumor fluorescence typically seen a few hours after the dose when the surgeon uses blue‑light visualization. In clinical studies, its use has been associated with higher rates of complete or more extensive resection of enhancing tumor and can improve the surgeon’s ability to distinguish tumor from normal brain, which may contribute to better progression‑free outcomes when combined with standard treatments. Compared with operating under white light alone, Gleolan does not replace other therapies but adds visual information that can make surgery more precise; there are few directly comparable alternatives, though some centers use other fluorescence agents or intraoperative imaging (such as MRI) for similar goals.

Typical dosing and how to take it
For adults undergoing surgery for suspected high‑grade glioma, the recommended dose is 20 mg/kg of actual body weight taken by mouth as a single dose 3 hours (range 2–4 hours) before induction of anesthesia. It is supplied as an oral solution prepared by healthcare staff; you are usually asked to drink the entire dose at one time with water, with or without food, as directed by the surgical team.

Special instructions
After taking Gleolan, you must avoid direct sunlight and bright indoor light for about 24 hours, including tanning beds and strong examination lamps; protective clothing and sunglasses are recommended if you must be in bright environments. Only the controlled blue‑light source used in the operating room should illuminate your brain tissue for visualization. Because the medicine is linked to liver effects, clinicians may review your liver tests before giving it, especially if you have known liver disease.

Missed dose and overdose
Gleolan dosing is coordinated closely with surgery timing, so if a dose is missed or not taken at the correct time, the surgical team will decide whether to delay or reschedule surgery or adjust plans; patients should not attempt to self‑correct timing without medical advice. In case of suspected overdose, treatment is supportive, with close monitoring, protection from light for a longer period, and management of symptoms such as low blood pressure or liver test elevations under hospital care.

Common side effects
Common effects include nausea, vomiting, low blood pressure, headache, pyrexia (fever), and transient increases in liver enzymes, most often occurring within hours to a day of dosing and usually mild to moderate in severity. Temporary skin and eye sensitivity to light (photosensitivity) is expected, which is why patients are instructed to avoid bright light for about 24 hours after taking the drug.

Serious or rare adverse effects
More serious reactions can include severe hypotension, significant liver enzyme elevations, severe photosensitivity reactions (such as blistering sunburn‑like rashes), or allergic/hypersensitivity reactions, including very rarely anaphylaxis. Any trouble breathing, chest pain, severe dizziness or fainting, or severe skin reaction after dosing should be treated as an emergency and reported to medical staff immediately.

Warnings and precautions
Because Gleolan can stress the liver, people with significant liver disease require careful risk–benefit assessment and possible extra monitoring; caution is also advised in severe kidney impairment. Safety in pregnancy is not well established, so it is generally used during pregnancy only if the potential benefit justifies the potential fetal risk; breastfeeding data are limited, and providers may recommend timing the dose and surgery to minimize infant exposure. The product is approved for adults, and use in children or adolescents is off-label and should be managed by specialists with experience in pediatric neurosurgery and neuro-oncology.

Safety compared with other options and reporting
Compared with many cancer medicines, Gleolan is given once and is generally well tolerated, but its unique risk of photosensitivity and potential liver effects mean that light‑exposure precautions and liver function awareness are important. Side effects can be reported to the surgical center, to the manufacturer’s patient safety line, or to national drug‑safety reporting programs such as FDA’s MedWatch, where up‑to‑date safety information and alerts are also made available.

Drug and supplement interactions
Gleolan can increase photosensitivity, so combining it with other photosensitizing medicines (such as certain antibiotics like tetracyclines or fluoroquinolones, some diuretics, sulfonylurea diabetes medicines, or herbal products like St. John’s wort) may heighten the risk of skin reactions in bright light. Because it can affect liver enzymes, additional caution is advised if you take other drugs that stress the liver, such as some chemotherapy agents or high‑dose acetaminophen; always provide a full list of prescription, over‑the‑counter, and herbal products to your surgical team.

Food, alcohol, and procedure interactions
Gleolan may be taken with or without food according to the anesthesia team’s fasting instructions before surgery; you must follow their guidance on when to stop eating and drinking. Alcohol should generally be avoided before surgery and may increase liver stress, so it is typically not recommended around the time of Gleolan administration. The medicine is designed specifically to interact with the blue‑light visualization system used in the operating room and does not usually interfere with standard diagnostic imaging like MRI or CT scans.

Precautions and monitoring
Use requires caution in patients with moderate to severe liver or kidney disease, in those with a history of severe photosensitivity disorders, and in individuals with prior serious reactions to 5‑aminolevulinic acid or similar compounds. Clinicians may check liver function tests before and after surgery in higher‑risk patients and will monitor blood pressure and other vital signs closely around the time of dosing and anesthesia.

Q: Is Gleolan a chemotherapy drug or does it treat my brain tumor directly?
A: Gleolan is not chemotherapy; it is an imaging agent that makes tumor cells glow under a special blue light so the surgeon can see and remove them more accurately during brain surgery.

Q: Why do I need to avoid sunlight and bright light after taking Gleolan?
A: After you take Gleolan, your skin and eyes are more sensitive to light for about 24 hours, so bright light can cause sunburn‑like skin reactions or eye discomfort, which is why you are asked to stay out of strong sunlight and use protective clothing and sunglasses.

Q: How long does Gleolan stay in my body?
A: Most of the drug and its active fluorescent compound are broken down and cleared within about a day, though light‑sensitivity precautions are usually recommended for at least 24 hours after dosing.

Q: Will I feel anything when the surgeon uses the blue light with Gleolan?
A: No, you are under anesthesia during surgery and cannot see or feel the blue light; it is used only by the surgical team to visualize the tumor.

Q: Can Gleolan be used more than once if I need another surgery?
A: In some cases, doctors may consider repeated use before another surgery, but this decision is individualized based on your overall health, liver function, prior tolerance, and the specifics of the planned operation.

Storage
Gleolan is usually stored, mixed, and given in the hospital or surgical center, so patients typically do not need to store it at home; if you are given the solution to drink, it should be taken exactly at the instructed time and not saved for later use.

Disposal
Any leftover product or containers are normally disposed of by healthcare staff according to medical facility procedures, so there is no special disposal step for the patient.